

**Module I: DES Preclinical Bioabsorbable Polymers,
Bioabsorbable Stents and Drug Coated Balloons***Moderators: Semih Oktay, PhD and Renu Virmani, MD*

8:00 AM	Scientific Perspective <i>Renu Virmani, MD</i>
8:05 AM	Industry Perspective: Bioabsorbable Polymer <i>John E. Shulze</i>
8:10 AM	Industry Perspective: Bioabsorbable Stent <i>Richard J Rapoza , PhD</i>
8:15 AM	FDA Engineers Perspective: Bioabsorbable Polymers and Stents <i>Erica Takai, PhD</i>
8:20 AM	Industry Perspective: Non-Polymeric Approach <i>Josiah N. Wilcox, PhD</i>
8:25 AM	Academic Perspective: Drug Coated Balloon <i>Bodo Cremers, MD</i>
8:30 AM	FDA Engineers Perspective: Drug Coated Balloon <i>Angela Smith</i>
8:35 AM	FDA Perspective: Animal and Clinical <i>Andrew Farb, MD</i>
8:40 AM	Panel Discussion with Audience Q&A: What Should be Modified in the Preclinical Studies to Develop the Third Generation of DES and Drug Eluting Balloons? <i>Moderator: S. Oktay</i> <i>Panelists: A. B. Boam, B. Cremers, A. Farb, R. J. Rapoza, J. E. Shulze, A. Smith, E. Takai, R. Virmani, J. N. Wilcox</i>

**Module II: DES Clinical Dual Antiplatelet Therapy:
Update of the Prospective Randomized Trial of
Prolonged Dual Antiplatelet Therapy after Stent
Implantation: Critical Issues***Moderators: Laura Mauri, MD and Jeffrey J. Popma, MD*

9:10 AM	Core Study Update: The State of the Study <i>Laura Mauri, MD</i>
9:15 AM	Remaining Challenges: CDRH Perspective <i>Rachel E. Behrman, MD, MPH</i>
9:20 AM	Pharma Perspective I <i>LeRoy A LeNarz, MD</i>
9:25 AM	Pharma Perspective II <i>William Daley, MD</i>
9:30 AM	Academic Projections <i>Jeffrey J. Popma, MD</i>
9:35 AM	Panel Discussion with Audience Q&A: DES Clinical Dual Antiplatelet Therapy: Update of the Prospective Randomized Trial of Prolonged Dual Antiplatelet Therapy after Stent Implantation: Critical Issues <i>Moderators: D. E. Cutlip, A. V. Kaplan</i> <i>Panelists: R. E. Behrman, A. B. Boam, A. Farb, K. A. Hicks, M. W. Krucoff, L. A. LeNarz, L. Mauri, J. J. Popma, C. A. Simonton, B. D. Zuckerman</i>
10:05 AM	Break

Module III: The New DES		11:25 AM	DES for Unprotected LM: Society Perspective <i>David R. Holmes, Jr., MD</i>
Guidance Document: Last Round			
<i>Moderator: Mitchell W. Krucoff, MD</i>			
10:20 AM	Comments Received and Possible Modifications <i>Elizabeth J. Hillebrenner</i>	11:30 AM	DES for Unprotected LM: FDA Perspective <i>Andrew Farb, MD</i>
10:30 AM	Industry Perspective <i>Sidney A. Cohen, MD, PhD</i>	11:35 AM	DES for Bifurcation: Clinical Trial Design: Start Up Company Perspective <i>Aaron V. Kaplan, MD</i>
10:35 AM	US Physician Perspective <i>Jeffrey J. Popma, MD</i>	11:40 AM	DES for Bifurcation: Industry Perspective <i>Krishna Sudhir, MD, PhD</i>
10:40 AM	Pre-Clinical Comments <i>Robert S. Schwartz, MD</i>		
10:45 AM	Panel Discussion with Audience Q&A: The New DES Guidance Document - Last Round <i>Moderator: M. W. Krucoff</i> <i>Panelists: A. B. Boam, S. A. Cohen, D. E. Cutlip, A. Farb, E. J. Hillebrenner, W. H. Maisel, H. Pinto, R. S. Schwartz</i>	11:45 AM	DES for Bifurcation: FDA Engineering Perspective <i>Kathryn O'Callaghan</i>
Module IV: Expansion Indications of DES Clinical Trial Design		11:50 AM	DES for Bifurcation: FDA Clinical Perspective <i>Andrew Farb, MD</i>
<i>Moderator: Mitchell W. Krucoff, MD</i>		11:55 AM	New Requirements for Second Generation BMS: FDA Update <i>Katharine J. Fronczak</i>
11:00 AM	DES for AMI: Industry Perspective <i>Josiah N. Wilcox, PhD</i>	12:00 PM	Panel Discussion: Expansion Indications of DES Clinical Trial Design <i>Moderator: M. W. Krucoff</i> <i>Panelists: H. L. Agler, A. B. Boam, K. Dawkins, A. Farb, K. J. Fronczak, D. R. Holmes, Jr., A. V. Kaplan, A. Kastrati, A. J. Kirtane, S. T. Normand, K. O'Callaghan, J. J. Popma, K. Sudhir</i>
11:05 AM	DES for AMI: Academic Perspective <i>Ajay J. Kirtane, MD, SM</i>		
11:10 AM	DES for AMI: FDA Perspective: Next Steps (Next AMI Trial, NSTEMI ACS) <i>Ashley B. Boam, MSBE</i>	12:30 PM	Lunch & Visit the Exhibits
11:15 AM	DES for Unprotected LM: Industry Perspective <i>Keith Dawkins, MD</i>		
11:20 AM	DES for Unprotected LM: Academic Perspective <i>Adnan Kastrati, MD</i>		

Module V: Should Live Cases be Broadcast to Meetings? Regulation in Education and Training		2:45 PM	Panel Discussion: Carotid Stenting and Embolic Protection <i>Moderator: W. A. Gray</i> <i>Panelists: C. Ahn, M. R. Jaff, K. Rocha-Singh, K. Rosenfield, J. Springer, S. Toor, MS</i>
1:30 PM	Interventional Cardiology Perspective <i>David R. Holmes, Jr., MD</i>		
1:35 PM	European Perspective <i>Horst Sievert, MD</i>	Lower Limb Interventions <i>Moderators: Allison Kumar, Krishna Rocha-Singh, MD and Timothy M. Sullivan, MD</i>	
1:40 PM	Medical Ethics Perspective <i>Charles R. Mackay, PhD</i>	3:00 PM	FDA Perspective: Differences in Peripheral Clinical Trial Designs <i>Allison Kumar</i>
1:45 PM	FDA Perspective <i>Bram D. Zuckerman, MD</i>	3:05 PM	CMS National Coverage Status of Peripheral Interventions <i>Marcel Salive, MD, MPH</i>
1:50 PM	Industry Perspective <i>Charles A. Simonton, MD</i>	3:10 PM	Next Steps in Trial Advancements for PAD <i>Krishna Rocha-Singh, MD</i>
1:55 PM	Short Introductory Film <i>Burt Cohen</i>	3:15 PM	Considerations for Critical Limb Ischemia Studies <i>TBA</i>
2:00 PM	Panel Discussion: Regulation in Education and Training <i>Moderator: M. W. Krucoff</i> <i>Panelists: D. E. Cutlip, K. Dawkins, D. R. Holmes, Jr., C. R. Mackay, H. Sievert, C. A. Simonton, R. Waksman, B. D. Zuckerman</i>	3:20 PM	Panel Discussion: Lower Limb Interventions <i>Moderator: K. J. Cavanaugh</i> <i>Panelists: W. A. Gray, V. Mukhi, M. Salive, A. Smith, J. Springer, T. M. Sullivan, S. Toor</i>
2:15 PM	Break		
Module VI: Update on Vascular Intervention: From Head to Toe			
<i>Carotid Stenting and Embolic Protection</i> <i>Moderators: Kenneth J. Cavanaugh, PhD and William A. Gray, MD</i>		Renal Artery Interventions <i>Moderators: Krishna Rocha-Singh, MD and Marcel Salive, MD, MPH</i>	
2:30 PM	FDA Clinical and Non-Clinical Perspective <i>Sadaf Toor, MS</i>	3:45 PM	FDA Perspective: Selecting and Supporting RAS Indications <i>Todd Courtney, MBA</i>
2:35 PM	What More Must be Shown to Advance Coverage? <i>William A. Gray, MD</i> <i>Marcel Salive, MD, MPH</i>	3:50 PM	Strategies for Primary Stenting Studies <i>Krishna Rocha-Singh, MD</i>
		3:55 PM	CMS Perspective: National Coverage <i>Marcel Salive, MD, MPH</i>

4:00 PM Panel Discussion: Renal Artery
Interventions
Moderator: T. M. Sullivan
Panelists: K. J. Cavanaugh, T. Courtney,
W. A. Gray, G. L. Kamer, K. Rocha-Singh,
J. Springer

Venous Interventions

Moderators: Kenneth J. Cavanaugh, PhD and
Krishna Rocha-Singh, MD

4:15 PM Considerations for Initiating Venous
Trials
Angela Smith

4:20 PM Panel Discussion: Venous Interventions
Moderator: W. A. Gray
Panelists: A. Kumar, H. Li, M. Salive,
A. Smith, J. Springer

4:30 PM Adjourn